No results for ‘’
Neuland Laboratories Ltd
₹16624
(0.99%)
Wed, 27 May 2026, 11:19 pm
Health Technology
Pharmaceuticals: Major
24.5KNeuland Laboratories PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 10.63 | 10.14 | 7.36 | 4.13 | 0 | 12.09 | 15.38 | 5.18 | 7.42 | 17.85 | 22.76 | 28.21 | 52.07 | 51.62 | 22.43 | 33.22 | 20.64 | 14.12 | 26.86 | 59.57 |
| Price to book ratio | 1.25 | 1.54 | 1.22 | 0.65 | 0.80 | 0.86 | 0.52 | 0.72 | 1.61 | 1.83 | 3.33 | 2.42 | 1.13 | 1.24 | 0.51 | 3.41 | 1.57 | 2.32 | 6.28 | 10.16 |
| Price to sales ratio | 0.41 | 0.45 | 0.38 | 0.16 | 0.20 | 0.16 | 0.09 | 0.16 | 0.43 | 0.62 | 1.25 | 2.33 | 1.23 | 1.31 | 0.49 | 2.90 | 1.41 | 1.96 | 5.25 | 10.66 |
| Price to cash flow ratio | 7.72 | 0 | 12.28 | 4.44 | 0 | 6.81 | 1.79 | 19.41 | 7.18 | 0 | 21.57 | 74.01 | 0 | 18.29 | 9.43 | 15.43 | 28.08 | 10.20 | 31.52 | 48.47 |
| Enterprise value | 1.01B | 1.61B | 2.08B | 2.38B | 2.75B | 2.83B | 2.57B | 2.84B | 3.88B | 4.66B | 7.94B | 14.94B | 9.23B | 10.35B | 5.73B | 28.35B | 15.34B | 23.78B | 80.37B | 152.85B |
| Enterprise value to EBITDA ratio | 1.45 | 8.46 | 10.05 | 9.34 | 10.48 | 6.31 | 4.93 | 4.63 | 5.30 | 7.13 | 10.12 | 15.53 | 25.14 | 24.15 | 6.84 | 20.62 | 11.88 | 8.83 | 18.02 | 48.69 |
| Debt to equity ratio | 0.79 | 1.31 | 1.95 | 2.64 | 3.41 | 3.17 | 2.89 | 2.14 | 1.53 | 1.16 | 0.98 | 0.35 | 0.57 | 0.33 | 0.37 | 0.23 | 0.29 | 0.13 | 0.07 | 0.10 |
| Return on equity % | 0 | 16.14 | 17.69 | 16.51 | -9.58 | 7.45 | 3.42 | 15.76 | 23.96 | 11.18 | 15.70 | 12.80 | 3.10 | 2.62 | 2.30 | 10.78 | 7.85 | 17.83 | 26.36 | 18.53 |
Neuland Laboratories Ltd Price to Earnings Ratio
The Neuland Laboratories Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Neuland Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Neuland Laboratories Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Neuland Laboratories Ltd (NSE: NEULANDLAB, BSE: 524558) is currently trading at ₹16624, with a market capitalization of ₹215.2B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Neuland Laboratories Ltd Price to Earnings Ratio is essential for fundamental analysis.
Neuland Laboratories Ltd Price to Earnings Ratio Current Value
The current Neuland Laboratories Ltd Price to Earnings Ratio stands at 59.57.
The latest Neuland Laboratories Ltd Price to Earnings Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Neuland Laboratories Ltd Price to Earnings Ratio Historical Trend
The Neuland Laboratories Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 59.57
- 2023: 26.86
- 2022: 14.12
- 2021: 20.64
- 2020: 33.22
The recent rise in Neuland Laboratories Ltd Price to Earnings Ratio suggests strengthening valuation trends and improving market sentiment.
What Neuland Laboratories Ltd Price to Earnings Ratio Indicates for Investors
The Neuland Laboratories Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Neuland Laboratories Ltd Price to Earnings Ratio Analysis Summary
The Neuland Laboratories Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Neuland Laboratories Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Neuland Laboratories Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.